Folate Functionalized Boron Nitride Nanotubes and their Selective Uptake by Glioblastoma Multiforme Cells: Implications for their Use as Boron Carriers in Clinical Boron Neutron Capture Therapy by Ciofani, Gianni et al.
NANO EXPRESS
Folate Functionalized Boron Nitride Nanotubes and their
Selective Uptake by Glioblastoma Multiforme Cells: Implications
for their Use as Boron Carriers in Clinical Boron Neutron
Capture Therapy
Gianni Ciofani Æ Vittoria Raffa Æ Arianna Menciassi Æ
Alfred Cuschieri
Received: 17 October 2008/Accepted: 11 November 2008/Published online: 25 November 2008
 to the authors 2008
Abstract Boron neutron capture therapy (BNCT) is
increasingly being used in the treatment of several
aggressive cancers, including cerebral glioblastoma multi-
forme. The main requirement for this therapy is selective
targeting of tumor cells by sufﬁcient quantities of
10B
atoms required for their capture/irradiation with low-
energy thermal neutrons. The low content of boron tar-
geting species in glioblastoma multiforme accounts for the
difﬁculty in selective targeting of this very malignant
cerebral tumor by this radiation modality. In the present
study, we have used for the ﬁrst time boron nitride nano-
tubes as carriers of boron atoms to overcome this problem
and enhance the selective targeting and ablative efﬁcacy of
BNCT for these tumors. Following their dispersion in
aqueous solution by noncovalent coating with biocompat-
ible poly-L-lysine solutions, boron nitride nanotubes were
functionalized with a ﬂuorescent probe (quantum dots) to
enable their tracking and with folic acid as selective tumor
targeting ligand. Initial in vitro studies have conﬁrmed
substantive and selective uptake of these nanovectors by
glioblastoma multiforme cells, an observation which con-
ﬁrms their potential clinical application for BNCT therapy
for these malignant cerebral tumors.
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Introduction
High-grade glioblastoma multiforme is uniformly fatal and
largely unresponsive to all available treatments. Patients
with these tumors usually survive for \1 year from the
time of ﬁrst diagnosis. Conventional surgical excision,
generally limited to the main tumor mass, does not remove
the microscopic foci of neoplastic cells that invade the
surrounding normal brain substance beyond the main tumor
mass, and are responsible for the inevitable tumor recur-
rence [1]. Conventional radiotherapy cannot ablate
completely these tumors [2], since this would require
unacceptably high radiation doses that result in severe
brain damage [3]. Boron neutron capture therapy (BNCT)
is a binary modality therapy that has the potential for
effective treatment of many forms of cancers, including
cerebral glioblastoma multiforme brain and melanomas
[4–6]. BNCT is based on the neutron capture reaction,
10B(n, a)
7Li, where a
10B atom captures a low-energy
thermal neutron and spontaneously decays to produce the
linear recoiling particles
4He (a particle) and
7Li. In tissues,
these particles have short penetration ranges, approxi-
mately the width of a single cell (5 lm for
7Li and 9 lm
for
4He). As the average linear energy transfer is high (
7Li,
162 keV/lm;
4He, 196 keV/lm), this results in densely
ionizing radiation restricted to the track of each particle [7,
8]. Thus, the essential requirement for effective BNCT is
selective targeting of tumor cells with sufﬁcient quantities
of
10B atoms (15–30 lg/g or more) and their irradiation
with low-energy thermal neutrons. In theory, BNCT is
potentially capable of killing individual cancer cells while
sparing the healthy normal parenchyma. Consequently,
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10B from boronated
drugs in cells of cancerous and normal tissues is of critical
importance [9]. The ideal drug would provide boron
selectively to tumor cells and would be nontoxic to normal
cells. Experimentally, cell culture tumor models provide a
useful approach for the investigation and understanding the
mechanisms of boron delivery by BNCT agents to cancer
and normal cells [10, 11]. The problem, however, is that
there is currently no truly satisfactory
10B target agent for
any human tumor type [12] although several boron agents
have been proposed and synthesized, but many of these
have either one or more disqualifying features [13]. The
ability of BNCT to fulﬁll its clinical therapeutic potential
thus clearly rests on the discovery and availability of
effective and safe boron transport agents.
In the present preliminary study, we have investigated
the use of boron nitride nanotubes (BNNTs) as boron atom
carriers. BNNTs are structural analog of carbon nanotubes
(CNTs) with alternating B and N atoms which entirely
substitute for C atoms in a graphitic-like sheet with almost
no change in atomic spacing. Thus, BNNTs are composed
of a substantial number of boron atoms (about 50%)
equivalents to hundreds to thousands per each nanotube.
Hence our hypothesis underlying the present investigation
is that BNNTs may serve as effective boron targets for
BNCT. BNNTs have generated considerable interest within
the scientiﬁc community by virtue of their unique proper-
ties. As with CNTs, they have various potentially useful
structural and electronic applications [14, 15] and share
good ﬂexibility with CNTs with a Young modulus of
1.22 ± 0.24 TPa [16, 17] but have superior chemical and
thermal stability. Together with their high resistance to
oxidation and stability [18], these properties mark BNNTs
as attractive potential candidates for a wide range of
applications. Nevertheless, in sharp contrast to the many
proposed biomedical applications of CNTs in recent years,
e.g., biosensors, DNA chip, nanovectors for drug, protein
and gene delivery [19], etc., the use of BNNTs in this ﬁeld
has been largely unexplored [20]. Cytocompatibility studies
and the interaction between BNNTs and living cells have
only been reported recently [21, 22] by our group and other
biomedical applications concerning their magnetic proper-
ties are actively under investigation in our laboratory.
In the present study, we realized stable dispersions of
BNNTs employing a positively charged protein (ploy-L-
lysine, PLL) as dispersion agent. Poly-L-lysine coated
BNNTs were then conjugated with ﬂuorescent molecules
(quantum dots) to enable their tracking in living cells. Folic
acid was used as a targeting ligand to functionalize BNNTs
against tumor cells, because of the ease of the reaction
procedureandthesmallsizeofthefolatemolecule,enabling
a stable binding with the nanotube coating, thus permitting
folate receptor-mediated endocytosis of PLL-BNNTs. To
date, folate has been used as a targeting ligand for both
tumor imaging and cancer chemotherapy [23–26].
The functionalized BNNTs were characterized by
imaging, Z-potential, size distribution, and UV–Vis spec-
tra. In vitro uptake tests were carried out on human
glioblastoma multiforme cells and on healthy human pri-
mary ﬁbroblasts as controls.
Materials and Methods
BNNT Dispersion and Functionalization
Boron nitride nanotubes provided by the Australian
National University, Canberra, Australia, were produced
by using a ball-milling and annealing method [27, 28].
These samples contain the
11B isotope. As the chemical
and biological interactions are independent on the isotope
type, we can assume the same results can be achieved with
10B containing (used in clinical BNCT). Details of sample
purity and composition (provided by the supplier) are as
follows: yield [80%, boron nitride [97 wt%, metal cata-
lysts (Fe and Cr) derived from the milling process
*1.5 wt% and absorbed O2 *1.5 wt%.
The polymer used for the aqueous suspension and dis-
persion of BNNTs was PLL obtained from Fluka (81339),
MW 70,000–150,000. All experiments were carried out in
phosphate buffered solution (PBS) as described previously
[21, 22]. Brieﬂy, samples of BNNT powder in a 0.1% PLL
solution were ultrasonicated for 12 h with a Branson so-
nicator 2510 (Bransonic). The output power of sonicator
was ﬁxed at 20 W for all experiments. Next, the sample
was centrifuged at 1,1009g for 10 min to remove nondi-
spersed residuals and impurities. Excess PLL was removed
by ultracentrifugation three times at 30,0009g for 30 min
at 4 C (Allegra 64R, Beckman) and stable PLL-BNNT
dispersion was obtained as a result of the noncovalent
coating of the nanotube walls with PLL.
Folate conjugation was achieved by linking the amino-
groups of PLL with the c carboxylic-groups of the folate
molecules, which are not involved in the folate receptor
interaction [29]. Folic acid (F7876 from Sigma), 3.5, and
5 mM 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide
(EDC, 03450 from Fluka) were added to a dispersion of
50 lg/mL of PLL-BNNT [30]. After reaction, the disper-
sion was ultracentrifuged (three times at 30,0009g for
30 min at 4 C) to remove unbound folic acid and EDC
resulting in stable dispersions of folate conjugated PLL-
BNNT (F-PLL-BNNT).
Spectrophotometric analysis was carried out with a
LIBRA S12 Spectrophotometer UV/Vis/NIR (Biochrom)
to characterize the dispersions and to quantify BNNT
concentrations [21].
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were covalently labeled with carboxyl derivatised quantum
dots for cellular tracking studies. Carboxyl quantum dots
were supplied by Invitrogen (Qdot
 605 ITK
TM
). The
conjugation reaction between the amino-groups of PLL and
carboxylic-groups of quantum dots was carried out as
speciﬁed by the supplier. Brieﬂy, 4 mL of PLL-BNNT
(50 lg/mL) were mixed with 4 lL of Qdots (8 lM) and
60 lL of EDC, 10 mg/mL, as activator. The solution was
gently stirred for 90 min at room temperature for optimal
conjugation and ﬁnally centrifuged (1,0009g, 10 min) to
remove large aggregates. Finally, ultracentrifugation (twice
at 30,0009g for 30 min at 4 C) was performed to remove
unbound quantum dots and obtain the labeled BNNT dis-
persions. Even if quenching of quantum dot ﬂuorescence
can occur because of some electron transfer between
BNNTs and ﬂuorescence dyes [31], the ﬁnal product
results perfectly suitable for biological tracking [22].
Sample size distribution was analysed with an N4plus
submicron particle size analyser (Beckman Coulter);
Z-potential measurement was performed with a Nano
Z-Sizer (Malvern Instrument). Each acquisition was per-
formed three times on aqueous nanotube suspensions of
concentration 1 lg/mL.
Samples were imaged by Focused Ion Beam (FIB)
microscopy which allows high contrast imaging [32]. For
this purpose, a small drop (10 lL) of PLL-BNNT disper-
sion (5 lg/mL) was placed onto a plasma-cleaned silicon
wafer and air dried. The FIB system used was a FEI 200
(Focused Ion Beam localized milling and deposition)
delivering a 30 keV beam of gallium ions (Ga
?). Figure 1a
shows well dispersed F-PLL-BNNTs after the completion
of the preparation procedure.
Cell Cultures and Viability Assay
Human glioblastoma multiforme T98G cells (ATCC CRL-
1690) were cultured in Dulbecco’s modiﬁed Eagle’s
medium with 10% fetal bovine serum, 100 IU/mL peni-
cillin, 100 lg/mL streptomycin, and 2 mM L-glutamine.
Primary human gingival ﬁbroblasts (gift from Dr. Stefania
Moscato, University of Pisa) were cultured in the same
medium with the addition of 10 ng/mL of epidermal
growth factor (EGF). Cells were maintained at 37 Ci na
saturated humidity atmosphere containing 95% air/5% CO2
and were seeded in a 24-well plate (30,000 cells/well).
For viability testing, MTT (3-(4,5-dimethylthiazole-
2-yl)-2,5-diphenyl tetrazolium bromide, M-2128 from
Sigma) cell proliferation assays were carried out after 24 h
of incubation with PLL-BNNT and F-PLL-BNNT modiﬁed
media, which contained 10% BNNT dispersion, corre-
sponding to a ﬁnal concentration of 10 lg/mL of BNNT.
After trypsinization and counting with a Burker chamber,
each cell culture was subdivided and seeded in six 96-well
plate chambers. Once the adhesion was veriﬁed (after about
6 h from the seeding) cells were incubated with MTT
0.5 mg/mL for 2 h. After cell treatment with 100 lLo f
DMSO (dimethyl sulfoxide, D8418 from Sigma) absor-
bance at 550 nm was measured with a VERSAMax
microplate reader (Molecular Devices). A reference control
test (k-) was carried out.
Cellular Uptake Studies
After adhesion (at 6 h), the cells were treated for 90 min
with the Qdots labeled PLL-BNNT and F-PLL-BNNT
modiﬁed culture medium (ﬁnal concentration 10 lg/mL of
BNNTs). In a control experiment, folic acid was added to
the cell culture medium to compete with the F-PLL-
BNNTs. For this competitive inhibition experiment, folic
Fig. 1 FIB image of well dispersed F-PLL-BNNTs (a); diagram of
the proposed nanovector (b)
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123acid was ﬁrst added to the medium at a concentration of
3.5 mM and cells were incubated for 30 min. Subse-
quently, F-PLL-BNNTs were added and the cells were
incubated for a further 90 min.
Lysosome tracking assays were carried out on glioblas-
toma cells with LysoTracker dye (L12491 from Invitrogen).
This is a ﬂuorescent acidotropic probe for labeling acidic
organelles in live cells. The probe ﬂuoresces when it accu-
mulates in cellular compartments with low pH. For these
studies, cells were incubated 2 h in a growth medium con-
taining LysoTracker in a dilution of 1:2,500 after 90 min
exposure to F-PLL-BNNT in the medium.
Cell imaging was carried out with a Nikon TE2000U
ﬂuorescent microscope equipped with a Nikon DS-5MC
USB2 cooled CCD camera. The cellular uptake of labeled
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123BNNT was determined by the ﬂuorescence intensity
obtained from the acquired images, and this provided a
measure of the nanotubes concentration inside the cells.
Before imaging, BNNT-incubated cells were washed three
times with PBS buffer after each experiment.
Each image was analysed with a dedicated MatLab
program for extrapolation of the ﬂuorescence intensity. In
particular, every color channel component (R, G, B) of the
images was analysed. The average intensity of the R
channel was then calculated and normalized to the maxi-
mum mean intensity obtained during all the experiments.
Statistical Analysis
The results were analysed by analysis of variance
(ANOVA) followed by Student’s t test to establish statis-
tical signiﬁcance which was set at 5%. MTT tests were
performed in sixplicate; while for ﬂuorescence analysis six
images were acquired for each experiment. In all cases,
three independent experiments were carried out. Results
are presented as mean value ± SEM.
Results and Discussion
BNNT Characterization
Figure 1a shows a FIB image of dispersed BNNTs. Since
the surface of many tumor cells over-expresses the folate
receptor, while the surface of the normal cells exhibits only
minimal expression, the folic acid functionalized PLL-
BNNTs can be internalized by the tumor cells though the
speciﬁc binding of the folic acid molecules present on the
wall of the functionalized BNNTs with the surface folate
Fig. 4 Fluorescence image of
glioblastoma cells incubated
with 10 lg/mL of Qdot
conjugated F-PLL-BNNTs (a);
PLL-BNNTs (c); F-PLL-
BNNTs with preincubation of
3.5 mM free folate (e). b, d, and
f are the corresponding bright
ﬁeld images
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123receptors of the tumor cells. The basic idea of this concept
is illustrated in Fig. 1b. A similar approach has been
reported to enhance cellular uptake of CNTs [30].
Spectrophotometric analysis was carried out after each
experiment to verify the binding of folic acid with the PLL-
BNNTs (Fig. 2). Folic acid exhibits a strong absorbance at
240 nm, a shoulder peak at about 290 nm, and a further
strong peak at 370 nm; whereas PLL-BNNTs have just one
absorbance peak at around 235 nm. F-PLL-BNNT disper-
sions exhibit a peak at 260 nm and a weak shoulder at
about 360 nm. These absorbance shifts resulted from the
interaction of PLL-BNNTs and folic acid, conﬁrming
successful chemical conjugation. The spectrum of a simple
mixture of PLL-BNNT dispersion with the solution of folic
acid, without reaction induced by EDC, was obtained as a
control which showed that both the peaks and the shoulder
peak of the folic acid were detectable at the same wave-
length as that of the ‘‘free’’ folate.
Z-potential analysis conﬁrmed the conjugation of folic
acid with the PLL-BNNTs by revealing a strong positive
Z-potential (43.4 ± 3.26 mV) for PLL-BNNTs; while a
shift to -32.0 ± 2.51 mV was found for the F-PLL-
BNNTs, thus indicating ‘‘masking’’ of the positive charges
of PLL by the folate molecules.
The size distribution studies yielded an average value of
242 ± 92 nm for PLL-BNNTs and 479 ± 223 nm for the
F-PLL-BNNTs.
In Vitro Experiments
Previously reported experiments, carried out on human
neuroblastoma cells, have conﬁrmed that these cells
maintain good viability after 24 h of treatment with 5.0 lg/
mL of polyethyleneimine coated BNNTs [22]. The present
cultures conﬁrmed the complete cytocompatibility of PLL-
BNNTs with both glioblastoma and primary ﬁbroblast
Fig. 5 Fluorescence image of
ﬁbroblast cells incubated with
10 lg/mL of Qdot conjugated
F-PLL-BNNTs (a); PLL-
BNNTs (c); F-PLL-BNNTs
with preincubation of 3.5 mM
free folate (e). b, d, and f are the
corresponding bright ﬁeld
images
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123cells. No differences in cell morphology were observed
between control (k-), PLL-BNNT and F-PLL-BNNT
treatment culture. Figure 3a–c shows images of the three
tests carried out on glioblastoma cells, whereas Fig. 3d–f
provides images of the same tests on healthy ﬁbroblast
cells. Cell viability assessed with Trypan blue assay was
[95% in each case. MTT assay, (Fig. 3g), provided clear
evidence for excellent metabolic activity after 24 h of
treatment. With both PLL-BNNT and F-PLL-BNNT
treatments, metabolic activity exceeded 80% of the control
for both the cell populations, with no signiﬁcant difference
between the experiments (n = 6; p[0.1).
The binding of the receptors and their ligands has the
characteristics of speciﬁcity, selectivity, strong afﬁnity, and
obvious biological effect. Thus in the present study, we
have demonstrated that PLL-coated BNNTs functionalized
with the folate ligand enable targeted uptake of the nano-
tubes by tumor cells by receptor-mediated endocytosis.
Even if the cells of glioblastoma multiforme do not have
the high level expression of folate receptors encountered in
other cancers [33], their increased expression relative to
normal brain cells is well documented [34] and there has
been several reports in the literature on targeted drug
delivery for this tumor based on folate ligands [34, 35]. The
folate ligand used in the present study to functionalize
BNNTs against tumor cells, is particularly attractive
because of the relative ease of the reaction procedure and
the small size of the folate molecule enabling a more stable
binding to the nanotube noncovalent PLL coating.
Qdots labeling of PLL-BNNTs allowed the direct visu-
alization of the uptake by glioblastoma and healthy
(control) ﬁbroblast cells. The ﬂuorescence image of glio-
blastoma cells after 90 min incubation in the presence of
F-PLL-BNNTs is shown by Fig. 4a, in which intensive
ﬂuorescence was clearly observed, indicating signiﬁcant
cellular uptake of nanotubes; Fig. 4b shows the corre-
sponding bright ﬁeld image.
In sharp contrast, ﬂuorescence of glioblastoma cells was
considerably weaker when the cells were incubated for
90 min in the presence of not folate-functionalized PLL-
BNNTs (Fig. 4c; with Fig. 4d corresponding bright ﬁeld
image). Figure 4e demonstrates that the folate-mediated
cellular uptake of F-PLL-BNNTs could be blocked by
competitive inhibition if a large amount of free folate
(3.5 mM) was added into the culture medium for 30 min
before the addition of F-PLL-BNNTs (Fig. 4f is the cor-
responding bright ﬁeld image).
The same experiments were carried out on normal
human gingival ﬁbroblasts which acted as controls. In these
experiments, similar but much weaker ﬂuorescence inten-
sity was detected in cultures treated with 10 lg/mL of F-
PLL-BNNTs (Fig. 5a; bright ﬁeld in Fig. 5b), with 10 lg/
mL of nonfolate-functionalized PLL-BNNTs (Fig. 5c;
bright ﬁeld in Fig. 5d), and ﬁnally treated with F-PLL-
BNNTs preceded by a preincubation of 3.5 mM free folate
(Fig. 5e; bright ﬁeld in Fig. 5f).
In summary, these results indicate that after 90 min of
incubation with labeled PLL-BNNTs, the presence of the
folate molecule on the BNNT coating strongly enhances
the uptake by glioblastoma cells, but no appreciable
improvement in uptake of the nanotubes is observed with
normal cultured ﬁbroblasts). Quantitative analysis of the
ﬂuorescence intensity, reported in Fig. 6a, conﬁrms these
data. The uptake of F-PLL-BNNTs by glioblastoma mul-
tiforme cells, in folate depleted medium, is statistically
different (p\0.001) and results in a 2-fold improvement
with respect to all the other treatments, which show no
statistically signiﬁcant differences (p[0.05).
Receptor-mediated endocytosis of F-PLL-BNNTs by
glioblastoma multiforme cells is conﬁrmed by Fig. 6b.
This microphotograph consists of a high-magniﬁcation
image of a glioblastoma cell following uptake of Qdot
conjugated F-PLL-BNNTs and lysosomal tracking. Yellow
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123ﬂuorescence arises from merging of Qdot (red) and Lyso-
Tracker probe (green) and demonstrates therefore a strong
accumulation of the nanovectors in the acidic compart-
ments (lysosomes) of the cells.
Conclusions
The results of recent and ongoing clinical trials which
conﬁrm the safety of BNCT for the treatment of cerebral
GBM highlight the immediate need for truly effective
boron target agents [36, 37]. In the present s study, we have
investigated the use of BNNTs as boron atom carriers.
After their dispersion in biocompatible PLL solutions,
BNNTs were functionalized with a ﬂuorescent probe and
with folic acid for tumor targeting.
The results obtained indicate that folate-functionalized
BNNTs have the potential to act as a boron delivery agents
to malignant glioblastoma cells as these preliminary in
vitro studies have conﬁrmed a strong and selective uptake
of these nanotubes vectors by glioblastoma multiforme
cells but not by normal human ﬁbroblasts. Obviously
extensive in vivo and preclinical tests are needed to explore
the use of functionalized BNNTS as boron target agents for
clinical BNCT [38].
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